The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for patients to switch between injection and infusion. Clinical trials showed similar efficacy and safety to IV dosing, with manageable side effects. LEQEMBI IQLIK is expected to launch in the U.S. in late August 2026, potentially improving access and adherence to Alzheimer's therapy.
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
Eisai and Biogen presented data at AAIC 2026 showing that LEQEMBI's subcutaneous autoinjector delivers similar efficacy and safety to intravenous administration for early Alzheimer's disease. The once-weekly 500 mg subcutaneous dose achieves comparab...
